Glycomimetics Has Started Dosing The First Cohort Of Healthy Volunteers In A Phase 1A Study Of GMI-1687 To Evaluate Safety, Tolerability, And Pharmacokinetics; Initial Results Are Expected By The End Of Q1 2024
Portfolio Pulse from Benzinga Newsdesk
Glycomimetics has begun dosing the first group of healthy volunteers in a Phase 1A study of GMI-1687. The study aims to evaluate the safety, tolerability, and pharmacokinetics of the drug. Initial results are expected by the end of Q1 2024.
September 06, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Glycomimetics has started a Phase 1A study of GMI-1687, which could potentially impact the company's stock depending on the results of the study.
The initiation of a Phase 1A study is a significant step in drug development. However, the impact on the stock price will depend on the results of the study, which are not yet available. Therefore, the short-term impact is neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100